Tonix strives for pandemic readiness with new US manufacturing facility

The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat
Vaccines for monkeypox, smallpox and COVID-19 are among some of the products that will be developed by Tonix Pharmaceuticals at its new clinical-scale manufacturing facility in North Dartmouth, Massachusetts.
The clinical-stage biopharma company officially launched its Advanced Development Center (ADC) with a ribbon cutting ceremony on Tuesday. Tonix plans to develop vaccines against infectious diseases at the new facility using its recombinant pox virus platform technology, which it says is ‘rapidly deployable for addressing potential novel or emerging pathogens.’
The 45,000 sq ft facility features single-use bioreactors and purification suites with equipment for GMP production of vaccines for clinical trials, including the capability to produce sterile vaccines in glass bottles. It has been designated a Biosafety Level 2 site, a Centers for Disease Control and Prevention label which means the microbes there pose moderate hazards to laboratorians and the environment.
According to Tonix Pharmaceuticals CEO Seth Lederman, the facility will accelerate development of vaccines targeting infectious diseases.
He commented: ‘The ADC greatly enhances our ability to progress our pipeline of vaccines for infectious diseases, including monkeypox, smallpox and COVID-19. We believe that the recombinant pox virus platform technology underlying our key vaccines in development, TNX-801, TNX-1840 and TNX-1850, coupled with our capabilities at the Tonix R&D Center (RDC) for research and development, will be rapidly deployable for addressing potential novel or emerging pathogens, with simplified distribution and administration, relative to modified mRNA-based vaccines.’
Lederman said the company’s goal is to ‘be able to design and test new recombinant pox virus vaccines against novel pathogens within the 100 days of recognition of a potential emerging pandemic threat’, noting that this timeline meets criteria set out by the White House Office of Science and Technology Policy.
Tonix’s portfolio features a range of investigational new drugs or biologics that are progressing through clinical trials. These include TNX-102 SL, a candidate in mid-Phase 3 development for the management of fibromyalgia, and TNX-102 SL, which is being developed to treat Long COVID.
Related News
-
News Valneva stock jumps as Pfizer invests more than €90M to support Lyme disease vaccine trial
VLA15 is the only Lyme disease vaccine candidate currently in clinical development -
News WHO to consider whether monkeypox should be classed as health emergency
A committee will meet next week to discuss issuing the emergency designation. -
News Evotec enters drug discovery collaboration with Janssen Pharmaceutica NV
Evotec and Janssen Pharmaceutica team up to discover novel therapeutic candidates -
News Niche start-ups spearheading cell and gene therapy innovation
Smaller companies targeting rare and extremely specific treatment areas are leading the charge in this emerging market. -
News BioNTech to start work on first African mRNA vaccine factory this month
The Rwanda site will be the first piece of the company’s African manufacturing network -
News Western countries consider stockpiles, place orders for vaccine against monkeypox
The US, Canada, UK, France, Germany, and Spain are among several countries to purchase vaccine doses. -
News GSK to acquire clinical-stage biopharma company Affinivax
The $3.3 billion deal will strengthen GSK’s vaccine pipeline. -
News Integrated service partners outperform standalone CDMOs in clinical development – Thermo Fisher
Engaging an integrated services partner could reduce risk and speed-up the process for drug sponsors.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance